GARDE : GC7 (N1-guanyl-1,7 Diaminoheptane) cARDiac arrEst

NCT07468292 | Not Yet Recruiting

• 1 other identifier: 25-AOIP-02
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Cardiac arrest (CA) with return of spontaneous circulation is associated with high mortality, exceeding 90% in out-of-hospital settings and approaching 50% in in-hospital settings. Despite management of the underlying cause of CA, patients often die from post-anoxic brain injury or from ischemia-reperfusion injury occurring after reperfusion and reoxygenation, which increases oxidative stress and leads to multi-organ failure. To date, no effective therapeutic strategy has been established in humans to limit these ischemia-reperfusion injuries. GC7 (N1-guanyl-1,7 diaminoheptane) has demonstrated a strong protective potential against ischemia reperfusion injury in rodent and porcine models, including myocardial infarction, stroke, and renal transplantation. These protective effects are attributed to the pleiotropic action of GC7 which renders cells and tissues energetically less dependent on oxygen, and reduces oxidative stress which play a major role in ischemia reperfusion injury. Degree of blood acidification and immune dysregulation may also represent parameters that GC7 could potentially influence. Although no adverse effects have been reported in these experimental models, GC7 has not yet been studied in human. Our study therefore aims to demonstrate the protective effect of GC7 on blood cells in patients after CA by evaluating oxidative stress levels, blood acidification and inflammatory profile.

Conditions

Cardiac Arrest (CA)

Keywords

cardiac arrest; GC7 (N1-guanyl-1,7 diaminoheptane); oxidative stress

Outcome Measures

Primary Outcomes (1)

• Blood oxidative stress levels

  at 24 hours after blood exposure to GC7

Secondary Outcomes (2)

• Blood acidification

  24 hours after blood exposure to GC7

• Blood inflammatory profile

  24 hours after blood exposure to GC7

Study Arms (1)

resuscitated cardiorespiratory arrest

EXPERIMENTAL

Other: GC7 exposure; Other: No GC7 exposure

Interventions

GC7 exposure OTHER

24-hour exposure of patient 's blood to GC7 molecule

resuscitated cardiorespiratory arrest

No GC7 exposure OTHER

No exposure of blood to GC7 molecule

resuscitated cardiorespiratory arrest

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Cardiac arrest as the primary reason for hospital admission
• Admission \< 48 hours
• Age ≥ 18 years
• Affiliated with a social security system

You may not qualify if:

• Limitation or withdrawal of life-sustaining therapies prior to study screening
• Prior cardio-vascular ischemic event (\> 24h) before cardiac arrest
• Patient deprived of liberty

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nice: lead

Study Sites (1)

CHU de Nice - Hôpital PASTEUR 2

Nice, France

Location

MeSH Terms

Conditions

Heart Arrest

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Central Study Contacts

Denis DOYEN, MD

CONTACT

+33492033615; doyen.d@chu-nice.fr

DOMINIQUE DONZEAU

CONTACT

+33492034560; donzeau.d@chu-nice.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 9, 2026
• First Posted: March 12, 2026
• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): July 1, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: March 16, 2026

Record last verified: 2026-03

Locations

FR (1)